The estimated Net Worth of William James Kennedy is at least $3.28 Milhão dollars as of 17 June 2020. Mr. Kennedy owns over 7,745 units of TG Therapeutics Inc stock worth over $2,183,183 and over the last 12 years he sold TGTX stock worth over $856,854. In addition, he makes $235,000 as Independent Director at TG Therapeutics Inc.
Sign up
Mr. Kennedy TGTX stock SEC Form 4 insiders trading
William has made over 4 trades of the TG Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 7,745 units of TGTX stock worth $141,501 on 17 June 2020.
The largest trade he's ever made was selling 25,071 units of TG Therapeutics Inc stock on 14 June 2018 worth over $337,205. On average, William trades about 4,864 units every 151 days since 2013. As of 17 June 2020 he still owns at least 94,633 units of TG Therapeutics Inc stock.
You can see the complete history of Mr. Kennedy stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Kennedy biography
Dr. William J. Kennedy Ph.D. serves as Independent Director of the Company. Dr. Kennedy is a regulatory-affairs professional with over 27 years of domestic and international experience. Prior to his retirement, Dr. Kennedy was Vice President for Regulatory Affairs for Zeneca Corporation. Dr. Kennedy has successfully managed the development, preparation, submission and approval of dozens of NDAs and major SNDAs. Dr. Kennedy has helped shape regulatory policy in the United States continuously since 1988, as a member and Chairman of the Pharmaceutical Research and Manufactures of America (“PhRMA”) Regulatory Affairs Coordinating Committee, as PhRMA’s Chief Negotiator with Congress and the Food and Drug Administration (“FDA”) for the FDA Modernization Act of 1997 (“FDAMA”), and as the Co-Chairman of PhRMA’s PDUFA III Steering Committee. Before joining the pharmaceutical industry, Dr. Kennedy was an Associate Research Professor at Yale Medical School. Dr. Kennedy is the author of several articles and is an often sought-after speaker for his insight into the regulatory process. He co-founded the website PDUFADate.com which provides regulatory opinions to the financial community. Dr. Kennedy was the recipient of the Regulatory Affairs Professional Society’s prestigious Special Recognition Award in 1998. Dr. Kennedy has been an independent consultant to the pharmaceutical industry since 1999. Based on Mr. Kennedy’s biotechnology and pharmaceutical industry experience, as well as his extensive management experience, the Board of Directors believes that Mr. Kennedy has the appropriate set of skills to serve as a member of the Board.
What is the salary of William Kennedy?
As the Independent Director of TG Therapeutics Inc, the total compensation of William Kennedy at TG Therapeutics Inc is $235,000. There are 6 executives at TG Therapeutics Inc getting paid more, with Michael Weiss having the highest compensation of $12,674,700.
How old is William Kennedy?
William Kennedy is 75, he's been the Independent Director of TG Therapeutics Inc since 2012. There are no older and 9 younger executives at TG Therapeutics Inc.
What's William Kennedy's mailing address?
William's mailing address filed with the SEC is 2 GANSEVOORT STREET, 9TH FLOOR, , NEW YORK, NY, 10014.
Insiders trading at TG Therapeutics Inc
Over the last 13 years, insiders at TG Therapeutics Inc have traded over $23,556,837 worth of TG Therapeutics Inc stock and bought 549,710 units worth $3,334,566 . The most active insiders traders include Capital Management, L.P.Kol..., Michael S Weiss, eSean A Power. On average, TG Therapeutics Inc executives and independent directors trade stock every 107 days with the average trade being worth of $1,103,023. The most recent stock trade was executed by Sagar Lonial on 17 June 2024, trading 25,933 units of TGTX stock currently worth $432,822.
What does TG Therapeutics Inc do?
tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".
What does TG Therapeutics Inc's logo look like?
Complete history of Mr. Kennedy stock trades at TG Therapeutics Inc
TG Therapeutics Inc executives and stock owners
TG Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Michael Weiss,
Executive Chairman of the Board, President, Chief Executive Officer -
Michael S. Weiss Esq.,
Chairman, CEO & Pres -
Sean Power,
Chief Financial Officer, Treasurer, Corporate Secretary -
Sean A. Power CPA, CPA,
CFO, Corp. Sec. & Treasurer -
Laurence Charney,
Independent Director -
Kenneth Hoberman,
Independent Director -
William Kennedy,
Independent Director -
Daniel Hume,
Independent Director -
Yann Echelard,
Independent Director -
Jenna Bosco,
Senior Vice President - Corporate Communications -
Sagar Lonial,
Independent Director -
Kelly Ross,
Chief Technology Officer -
Adam Waldman,
Chief Commercial Officer -
Dr. Owen A. O'Connor,
Chief Scientific Officer -
Biotechnologies S.A.S.U. Lfb,
10% owner -
Mark Schoenebaum,
Director -
Neil Herskowitz,
Director -
Capital Management, L.P.Kol...,